Immatics Biotechnologies GmbH - Product Pipeline Review - 2016

Published: Feb, 2016 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immatics Biotechnologies GmbH - Product Pipeline Review - 2016

Summary


Global Markets Direct's, 'immatics biotechnologies GmbH - Product Pipeline Review - 2016', provides an overview of the immatics biotechnologies GmbH's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by immatics biotechnologies GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of immatics biotechnologies GmbH
- The report provides overview of immatics biotechnologies GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses immatics biotechnologies GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features immatics biotechnologies GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy


- Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for immatics biotechnologies GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding immatics biotechnologies GmbH's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Immatics Biotechnologies GmbH Snapshot 6
Immatics Biotechnologies GmbH Overview 6
Key Information 6
Key Facts 6
Immatics Biotechnologies GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Immatics Biotechnologies GmbH - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Immatics Biotechnologies GmbH - Pipeline Products Glance 15
Immatics Biotechnologies GmbH - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Immatics Biotechnologies GmbH - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Immatics Biotechnologies GmbH - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Immatics Biotechnologies GmbH - Drug Profiles 20
IMA-901 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IMA-910 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
APVAC-1 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
APVAC-2 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IMA-950 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
IMA-101 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IMA-102 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
IMA-201 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IMA-202 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
IMA-203 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
IMA-300 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IMA-301 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein for Solid Tumors 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Immatics Biotechnologies GmbH - Pipeline Analysis 38
Immatics Biotechnologies GmbH - Pipeline Products by Target 38
Immatics Biotechnologies GmbH - Pipeline Products by Route of Administration 39
Immatics Biotechnologies GmbH - Pipeline Products by Molecule Type 40
Immatics Biotechnologies GmbH - Recent Pipeline Updates 41
Immatics Biotechnologies GmbH - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Immatics Biotechnologies GmbH, Key Information 6
Immatics Biotechnologies GmbH, Key Facts 6
Immatics Biotechnologies GmbH - Pipeline by Indication, 2016 8
Immatics Biotechnologies GmbH - Pipeline by Stage of Development, 2016 9
Immatics Biotechnologies GmbH - Monotherapy Products in Pipeline, 2016 10
Immatics Biotechnologies GmbH - Partnered Products in Pipeline, 2016 11
Immatics Biotechnologies GmbH - Partnered Products/ Combination Treatment Modalities, 2016 12
Immatics Biotechnologies GmbH - Out-Licensed Products in Pipeline, 2016 13
Immatics Biotechnologies GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Immatics Biotechnologies GmbH - Phase III, 2016 15
Immatics Biotechnologies GmbH - Phase II, 2016 16
Immatics Biotechnologies GmbH - Phase I, 2016 17
Immatics Biotechnologies GmbH - Preclinical, 2016 18
Immatics Biotechnologies GmbH - Discovery, 2016 19
Immatics Biotechnologies GmbH - Pipeline by Target, 2016 38
Immatics Biotechnologies GmbH - Pipeline by Route of Administration, 2016 39
Immatics Biotechnologies GmbH - Pipeline by Molecule Type, 2016 40
Immatics Biotechnologies GmbH - Recent Pipeline Updates, 2016 41
Immatics Biotechnologies GmbH, Subsidiaries 44